source
- Design Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from ChinaPlus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich's ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led to an average 6.4-point improveme…Endpoints · 2mo ago↗ source
- Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drugThe agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.BioPharma Dive · 2mo ago↗ source
- Merck's ADC sac-TMT gets its first global Phase 3 win ahead of scheduleAn experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the pat…